Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Arrowhead presented interim Phase 1/2a data for ARO-INHBE at EASL 2026, showing a 44% placebo-adjusted reduction in liver fat content in obese patients with baseline liver fat >8%. The RNAi therapy also demonstrated dose-dependent Activin E reductions of up to 85.3% and enhanced visceral fat reduction when combined with low-dose tirzepatide.
Key figures
- Drug Name
- ARO-INHBE
- Phase Of Trial
- Phase 1/2a
- Study population size
- 78
- Activin e reduction max
- 85.3%
- Liver fat reduction placebo adjusted
- 44%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.